Canaccord Genuity Maintains Buy on Travere Therapeutics, Raises Price Target to $70

Benzinga · 1d ago
Canaccord Genuity analyst Edward Nash maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $62 to $70.